Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $297M bought by 75 insiders at 59 companies
  • $342M sold by 51 insiders outside a trading plan
  • $2.6B sold by 246 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past week, each insider's filings added up.

  1. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M
  2. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    1,815,552 shares at $34.14 Oct 14–20, 5 filings +1.4% to stake 2 superinvestors bought in Q2
    $62M
  3. PAMPampa Energia
    Marcos Marcelo MindlinDirector
    435,000 shares at $80.78 Oct 15 +6.4% to stake
    $35.1M
  4. PEPPepsiCo
    Robert C PohladDirector
    184,646 shares at $128.28 Oct 14 +74% to stake 3 superinvestors bought in Q2
    $23.7M
  5. DOLEDole PLC
    Pale Fire Capital SE10% owner, +4 joint filers
    648,356 shares at $13.19 Oct 20–22 +6.7% to stake
    $8.6M
  6. APLDApplied Digital
    Jason Gechen ZhangPresident
    300,000 shares at $18.86 Oct 16 +12% to stake 5 superinvestors bought in Q2
    $5.7M
  7. BORRBorr Drilling
    Tor Olav TroimDirector
    500,000 shares at $4.60 Oct 15 +1.3% to stake
    $2.3M
  8. RENTRent the Runway
    Nexus Capital Management LPDirector, +9 joint filers
    632,922 shares at $3.55 Oct 21 +15% to stake
    $2.2M
  9. RENTRent the Runway
    CHS US Investments LLC10% owner, +4 joint filers
    458,245 shares at $3.55 Oct 21 +2% to stake
    $1.6M
  10. FBKFB Financial
    Orrin H Ingram IIDirector
    29,081 shares at $52.88 Oct 20 +31% to stake
    $1.5M

Biggest sales

Past week, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    43,111 shares at $46,654.38 Oct 20 0.5% of stake Planned sale (10b5-1)
    $2B
  2. INSWInternational Seaways
    Famatown Finance Ltd10% owner, +2 joint filers
    1,106,190 shares at $97.01 Apr 30–Oct 8 14% of stake
    $107M
  3. SNOWSnowflake
    Frank SlootmanDirector
    300,000 shares at $316.43 Oct 19 94% of stake Planned sale (10b5-1)
    $94.9M
  4. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    4,893,590 shares at $17.55 Oct 15–19, 2 filings 17% of stake
    $85.9M
  5. TRVTravelers
    Alan D SchnitzerCEO
    88,900 shares at $396.77 Oct 21 23% of stake
    $35.3M
  6. PATHUiPath
    Daniel DinesCEO
    2,500,000 shares at $13.23 Oct 15–16 7.9% of stake Planned sale (10b5-1)
    $33.1M
  7. UTHRUnited Therapeutics
    Martine A RothblattCEO
    47,500 shares at $547.72 Oct 15–21, 5 filings 13% of stake Planned sale (10b5-1)
    $26M
  8. MUMicron Technology
    Scott J DeboerPres. & Chief Tech & Prod Offr
    28,545 shares at $900.00 Oct 16 16% of stake Planned sale (10b5-1)
    $25.7M
  9. NTRANatera
    Matthew RabinowitzChair
    50,000 shares at $402.64 Oct 15 2.3% of stake Planned sale (10b5-1)
    $20.1M
  10. AFLAflac
    Japan Post Holdings Co., Ltd.10% owner
    168,611 shares at $118.29 Oct 14–15, 2 filings 0.3% of stake Planned sale (10b5-1)
    $19.9M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 6 insiders, $1.7M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

    Latest buy Oct 23 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

SER insider trades

Every open-market buy and sale in SER, one row per filing, newest first

SER page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. Stephen K. Brannan Director
    SERSerina Therapeutics
    Buy
    $2,030 1,000 shares at $2.03 New stake
    Traded Jul 7 Filed Jul 9
    ↗
  2. Jay Venkatesan Director
    SERSerina Therapeutics
    Buy
    $1,048 589 shares at $1.78 New stake
    Traded May 22 Filed Jun 22
    ↗
  3. Karen J Wilson Director
    SERSerina Therapeutics
    Buy
    $18K 10,100 shares at $1.76 New stake
    Traded Jun 11–12 Filed Jun 15
    ↗
  4. Karen J Wilson Director
    SERSerina Therapeutics
    Buy
    $37K 20,000 shares at $1.85 New stake
    Traded May 21–22 Filed May 26
    ↗
  5. Richard Peter Marshall Director
    SERSerina Therapeutics
    Buy
    $20K 12,183 shares at $1.65 New stake
    Traded May 19 Filed May 22
    ↗
  6. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $19K 6,500 shares at $2.86 100% of stake
    Traded Mar 23 Filed Mar 24
    ↗
  7. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $98K 39,000 shares at $2.50 100% of stake
    Traded Mar 19 Filed Mar 20
    ↗
  8. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $20K 6,500 shares at $3.03 100% of stake
    Traded Feb 2 Filed Feb 3
    ↗
  9. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $23K 6,500 shares at $3.57 100% of stake
    Traded Jan 28 Filed Jan 29
    ↗
  10. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $7,375 2,500 shares at $2.95 100% of stake
    Traded Jan 22 Filed Jan 23
    ↗
  11. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $12K 4,000 shares at $3.04 100% of stake
    Traded Jan 20–21 Filed Jan 21
    ↗
  12. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $16K 6,500 shares at $2.50 100% of stake
    Traded Jan 13–14 Filed Jan 14
    ↗
  13. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $35K 13,000 shares at $2.69 100% of stake
    Traded Jan 8 Filed Jan 9
    ↗
  14. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $11K 4,100 shares at $2.60 100% of stake
    Traded Dec 23, 2025 Filed Dec 29, 2025
    ↗
  15. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $15K 5,673 shares at $2.67 100% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗
  16. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $9,562 3,227 shares at $2.96 100% of stake
    Traded Dec 16, 2025 Filed Dec 17, 2025
    ↗
  17. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $5,541 1,700 shares at $3.26 100% of stake
    Traded Dec 12, 2025 Filed Dec 16, 2025
    ↗
  18. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $12K 3,555 shares at $3.24 100% of stake
    Traded Dec 11, 2025 Filed Dec 12, 2025
    ↗
  19. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $4,149 1,245 shares at $3.33 100% of stake
    Traded Dec 9–10 Filed Dec 11, 2025
    ↗
  20. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $23K 6,500 shares at $3.61 100% of stake
    Traded Dec 2–3 Filed Dec 4, 2025
    ↗
  21. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $23K 5,965 shares at $3.90 50% of stake
    Traded Nov 25, 2025 Filed Nov 26, 2025
    ↗
  22. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $2,105 535 shares at $3.94 100% of stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗
  23. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $24K 6,500 shares at $3.75 100% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
    ↗
  24. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $27K 6,500 shares at $4.10 100% of stake
    Traded Nov 10, 2025 Filed Nov 12, 2025
    ↗
  25. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $14K 3,398 shares at $4.24 100% of stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  26. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $14K 3,102 shares at $4.40 100% of stake
    Traded Nov 4, 2025 Filed Nov 5, 2025
    ↗
  27. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $28K 5,551 shares at $4.96 100% of stake
    Traded Oct 28, 2025 Filed Oct 29, 2025
    ↗
  28. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $4,921 949 shares at $5.19 100% of stake
    Traded Oct 27, 2025 Filed Oct 28, 2025
    ↗
  29. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $32K 6,500 shares at $4.97 100% of stake
    Traded Oct 20, 2025 Filed Oct 21, 2025
    ↗
  30. Randall Moreadith Chief Scientific Officer
    SERSerina Therapeutics
    Planned sale
    $22K 4,326 shares at $5.20 100% of stake
    Traded Oct 13, 2025 Filed Oct 14, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.